Cash use for operations for the first half of 2024 is expected to be $35 to $45 million, driven primarily by expenses for our clinical program in Alzheimer’s disease
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAVA:
- Short Report: Bears squeeze MicroStrategy as shares track bitcoin higher
- Cassava Sciences Announces Key Development with Press Release
- Cassava Sciences call volume above normal and directionally bullish
- No Decline in Cognition Scores in Patients with Mild Alzheimer’s Disease Who Received Simufilam Continuously For 24 Months
- Cassava Sciences reports results of two-year study of simufilam
